Active, not recruitingPhase 4NCT06352073
Dupilumab for Eosinophilic Esophagitis With Severe Strictures
Studying Primary eosinophilic gastrointestinal disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of North Carolina, Chapel Hill
- Principal Investigator
- Evan S Dellon, MD, MPHUniversity of North Carolina, Chapel Hill
- Intervention
- Dupilumab(drug)
- Enrollment
- 23 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2024 – 2026
Study locations (1)
- University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Collaborators
Regeneron Pharmaceuticals · Sanofi
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06352073 on ClinicalTrials.govOther trials for Primary eosinophilic gastrointestinal disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06851559A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 WeeksPhathom Pharmaceuticals, Inc.
- RECRUITINGNANCT06817213Patient-Centered Decision Support for Eosinophilic EsophagitisUniversity of Michigan
- RECRUITINGNCT06695897A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in GermanySanofi
- RECRUITINGNANCT06381219Pediatric Eosinophilic Esophagitis (pedEoE): Effect of Allergen Heat Denaturation on EoE Remission: a Pilot TrialUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGNCT06991881Eosinophilic Esophagitis: Towards Improved ManagementOslo University Hospital
- RECRUITINGNANCT06501274Capsule Sponge Study in Eosinophilic OesophagitisEast and North Hertfordshire NHS Trust
- RECRUITINGNANCT05730933An Intervention Study to Improve Therapeutic Compliance in Adult Patients With Eosinophilic Esophagitis.Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- RECRUITINGPHASE1, PHASE2NCT05608681A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).Eupraxia Pharmaceuticals Inc.
See all trials for Primary eosinophilic gastrointestinal disease →